These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15317463)

  • 1. Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity.
    Chen P; Doweyko AM; Norris D; Gu HH; Spergel SH; Das J; Moquin RV; Lin J; Wityak J; Iwanowicz EJ; McIntyre KW; Shuster DJ; Behnia K; Chong S; de Fex H; Pang S; Pitt S; Shen DR; Thrall S; Stanley P; Kocy OR; Witmer MR; Kanner SB; Schieven GL; Barrish JC
    J Med Chem; 2004 Aug; 47(18):4517-29. PubMed ID: 15317463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.
    Chen P; Norris D; Das J; Spergel SH; Wityak J; Leith L; Zhao R; Chen BC; Pitt S; Pang S; Shen DR; Zhang R; De Fex HF; Doweyko AM; McIntyre KW; Shuster DJ; Behnia K; Schieven GL; Barrish JC
    Bioorg Med Chem Lett; 2004 Dec; 14(24):6061-6. PubMed ID: 15546730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; McGowan DC; Armistead DM; Boucher C; Buchanan JL; Buckner W; Chai L; Elbaum D; Epstein LF; Faust T; Flynn S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Lee JH; Metz D; Middleton S; Mohn D; Morgenstern K; Morrison MJ; Novak PM; Oliveira-dos-Santos A; Powers D; Rose P; Schneider S; Sell S; Tudor Y; Turci SM; Welcher AA; White RD; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Amouzegh P; Ermann M; Jenkins J; Johnston D; Napier S; Power E
    J Med Chem; 2006 Aug; 49(16):4981-91. PubMed ID: 16884310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor.
    Das J; Chen P; Norris D; Padmanabha R; Lin J; Moquin RV; Shen Z; Cook LS; Doweyko AM; Pitt S; Pang S; Shen DR; Fang Q; de Fex HF; McIntyre KW; Shuster DJ; Gillooly KM; Behnia K; Schieven GL; Wityak J; Barrish JC
    J Med Chem; 2006 Nov; 49(23):6819-32. PubMed ID: 17154512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Buchanan JL; Buckner WH; Cee VJ; Chai L; Deak HL; Epstein LF; Faust T; Gallant P; Geuns-Meyer SD; Gore A; Gu Y; Henkle B; Hodous BL; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; Masse CE; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; White RD; Zhao H; Zhu L; Zhu X
    J Med Chem; 2006 Sep; 49(19):5671-86. PubMed ID: 16970394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of thienopyridines as Src-family selective Lck inhibitors.
    Abbott L; Betschmann P; Burchat A; Calderwood DJ; Davis H; Hrnciar P; Hirst GC; Li B; Morytko M; Mullen K; Yang B
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1167-71. PubMed ID: 17234410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection.
    Burchat A; Borhani DW; Calderwood DJ; Hirst GC; Li B; Stachlewitz RF
    Bioorg Med Chem Lett; 2006 Jan; 16(1):118-22. PubMed ID: 16216497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases.
    Thaimattam R; Daga PR; Banerjee R; Iqbal J
    Bioorg Med Chem; 2005 Aug; 13(15):4704-12. PubMed ID: 15914012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and initial SAR of imidazoquinoxalines as inhibitors of the Src-family kinase p56(Lck).
    Chen P; Norris D; Iwanowicz EJ; Spergel SH; Lin J; Gu HH; Shen Z; Wityak J; Lin TA; Pang S; De Fex HF; Pitt S; Shen DR; Doweyko AM; Bassolino DA; Roberge JY; Poss MA; Chen BC; Schieven GL; Barrish JC
    Bioorg Med Chem Lett; 2002 May; 12(10):1361-4. PubMed ID: 11992777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.
    Goldberg DR; Butz T; Cardozo MG; Eckner RJ; Hammach A; Huang J; Jakes S; Kapadia S; Kashem M; Lukas S; Morwick TM; Panzenbeck M; Patel U; Pav S; Peet GW; Peterson JD; Prokopowicz AS; Snow RJ; Sellati R; Takahashi H; Tan J; Tschantz MA; Wang XJ; Wang Y; Wolak J; Xiong P; Moss N
    J Med Chem; 2003 Apr; 46(8):1337-49. PubMed ID: 12672234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-Anilino-7,8-dialkoxybenzo[g]quinoline-3-carbonitriles as potent Src kinase inhibitors.
    Berger DM; Dutia M; Birnberg G; Powell D; Boschelli DH; Wang YD; Ravi M; Yaczko D; Golas J; Lucas J; Boschelli F
    J Med Chem; 2005 Sep; 48(19):5909-20. PubMed ID: 16161995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lead validation and SAR development via chemical similarity searching; application to compounds targeting the pY+3 site of the SH2 domain of p56lck.
    Macias AT; Mia MY; Xia G; Hayashi J; MacKerell AD
    J Chem Inf Model; 2005; 45(6):1759-66. PubMed ID: 16309282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I.
    Zhang G; Ren P; Gray NS; Sim T; Liu Y; Wang X; Che J; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Chow D; Martin Seidel H; Karanewsky DS; He Y
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5618-21. PubMed ID: 18793846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and preliminary SAR.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Buchanan JL; Buckner WH; Cheng A; Faust T; Hsieh F; Huang X; Lee JH; Marshall TL; Martin MW; McGowan DC; Schneider S; Turci SM; White RD; Zhu X
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2305-9. PubMed ID: 17280833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Kim D; Wang L; Beconi M; Eiermann GJ; Fisher MH; He H; Hickey GJ; Kowalchick JE; Leiting B; Lyons K; Marsilio F; McCann ME; Patel RA; Petrov A; Scapin G; Patel SB; Roy RS; Wu JK; Wyvratt MJ; Zhang BB; Zhu L; Thornberry NA; Weber AE
    J Med Chem; 2005 Jan; 48(1):141-51. PubMed ID: 15634008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validated quantitative structure-activity relationship analysis of a series of 2-aminothiazole based p56(Lck) inhibitors.
    Li J; Du J; Xi L; Liu H; Yao X; Liu M
    Anal Chim Acta; 2009 Jan; 631(1):29-39. PubMed ID: 19046675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ring-fused pyrazole derivatives as potent inhibitors of lymphocyte-specific kinase (Lck): Structure, synthesis, and SAR.
    Takayama T; Umemiya H; Amada H; Yabuuchi T; Koami T; Shiozawa F; Oka Y; Takaoka A; Yamaguchi A; Endo M; Sato M
    Bioorg Med Chem Lett; 2010 Jan; 20(1):112-6. PubMed ID: 19945867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.